Usability, participant acceptance, and safety of a prefilled insulin injection device in a 3-month observational survey in everyday clinical practice in Australia

Journal of Diabetes Science and Technology

Volumn 3, Issue 6, 2009, Pages 1425-1438

  Carter, John ^a,b   Beilin, Jonathan ^c   Morton, Adam ^d   De Luise, Mario ^e  

^a Concord and Hornsby Hospitals ^*  (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

^d MATER HOSPITAL   (Australia)

^e AUSTIN HOSPITAL   (Australia)

Author keywords

Clinical practice; Diabetes; Insulin glargine; Safety; SoloSTAR

Indexed keywords

ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLARGINE; INSULIN;

ADULT; AGED; ATTITUDE TO HEALTH; AUSTRALIA; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; EQUIPMENT DESIGN; FEMALE; HEALTH CARE SURVEY; HUMAN; INJECTION; INSTRUMENTATION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PATIENT ATTITUDE; PATIENT EDUCATION; PATIENT SATISFACTION; PROSPECTIVE STUDY; PUBLICATION; SAFETY; TIME; TREATMENT OUTCOME;

ADULT; AGED; AUSTRALIA; CONSUMER PRODUCT SAFETY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; FEMALE; HEALTH CARE SURVEYS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS; INSULIN; MALE; MIDDLE AGED; PAMPHLETS; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT EDUCATION AS TOPIC; PATIENT SATISFACTION; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 77956139296     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680900300624     Document Type: Article

References (14)

1. Bohannon NJ. Insulin delivery using pen devices. Simple-to-use tools may help young and old alike. Postgrad Med. 1999;106(5):57-8, 61-4, 68.
2. Graff MR, McClanahan MA. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin Ther. 1998;20(3):486-96. (Pubitemid 28343501)
3. Klonoff DC. The pen is mightier than the needle (and syringe). Diabetes Technol Ther. 2001;3(4):631-3. (Pubitemid 34202922)
4. Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther. 2004;26(9):1498-505. (Pubitemid 39572159)
5. Clarke A, Dain MP. Dose accuracy of a reusable insulin pen using a cartridge system with an integrated plunger mechanism. Expert Opin Drug Deliv. 2006;3(5):677-83. (Pubitemid 44389028)
6. Clarke A, Spollett G. Dose accuracy and injection force dynamics of a novel disposable insulin pen. Expert Opin Drug Deliv. 2007;4(2):165-74. (Pubitemid 46389914)
7. Robertson KE, Glazer NB, Campbell RK. The latest developments in insulin injection devices. Diabetes Educ. 2000;26(1):135-8, 141-6, 149-52.
8. Haak T, Edelman S, Walter C, Lecointre B, Spollett G. Comparison of usability and patient preference for the new disposable insulin device Solostar versus Flexpen, lilly disposable pen, and a prototype pen: an open-label study. Clin Ther. 2007;29(4):650-60. (Pubitemid 47016637)
9. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, Landgraf R, Kleinebreil L, International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28(11):2673-9. (Pubitemid 43951158)
10. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28(10):2543-5. (Pubitemid 41384310)
11. Golden SH, Selvin E, Cunningham KE. Glycaemic status and cardiovascular disease in type 2 diabetes mellitus: re-visiting glycated haemoglobin targets for cardiovascular disease prevention. Diabetes Obes Metab. 2007;9(6):792-8. (Pubitemid 47555202)
12. Carter J, Roberts A. Usability of a pre-filled insulin injection device in a 3-month observational survey of everyday clinical practice in Australia. Curr Med Res Opin. 2008;24(10):2741-9.
13. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-53. (Pubitemid 38579764)
14. Gerstein HC, Yale JF, Harris SB, Issa M, Stewart JA, Dempsey E. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med. 2006;23(7):736-42. (Pubitemid 44366071)